Welcome to our dedicated page for BIMUF news (Ticker: BIMUF), a resource for investors and traders seeking the latest updates and insights on BIMUF stock.
Historical news and press releases for Pascal Biosciences Inc. (BIMUF) cover the company's biotechnology research activities and eventual transformation into Nevis Brands. During its operation as Pascal Biosciences, news focused on immuno-oncology research programs, cannabinoid therapeutics development, and regulatory approvals for research activities. The company announced research collaborations, intellectual property filings, and advances in its cancer immunotherapy programs.
Following the business transformation, news coverage shifted to reflect the pivot from biotechnology to cannabis beverages. Announcements detailed the name change to Nevis Brands, the introduction of hemp-derived THC products, and the company's licensing strategy for market expansion. The BIMUF ticker was replaced with new trading symbols as part of this corporate restructuring.
Investors reviewing historical Pascal Biosciences news should note that the company no longer operates in the biotechnology sector. Current developments relate to Nevis Brands' cannabis beverage business rather than pharmaceutical research. Historical news about immuno-oncology programs, cannabinoid research, and biotech partnerships pertains to discontinued operations under the Pascal Biosciences name.
Pascal Biosciences (OTC PINK:BIMUF) announced significant management changes following a capital raise. Chairman Karoly Nikolich will step down, while Vice President Kevin Egan has been promoted to Chief Business Officer due to his extensive biotech experience. CFO Judi Dalling will retire at the end of April. The company is focused on developing therapies for serious diseases like cancer and COVID-19, with ongoing clinical trials for promising candidates such as PAS-403 and PAS-393. These leadership changes might facilitate new partnerships and advancements in their programs.
Pascal Biosciences (OTC PINK:BIMUF) has successfully closed the second tranche of a non-brokered private placement, raising $190,000 from the issuance of 1,900,000 units. This follows a first tranche that raised $560,000 in February 2021. Each unit includes one share and a warrant, allowing the purchase of additional shares at $0.15 for 24 months. The proceeds will bolster working capital, supporting their biotech initiatives focused on serious diseases like cancer and COVID-19. Notably, insiders purchased 1,255,000 units, reflecting strong confidence from existing shareholders.
